VTV publishes on Phase 2 diabetes study

vTv Therapeutics Inc. (NASDAQ:VTVT) has announced publishing a paper in the Science Translational Medicine detailing the discovery as well as development of an investigational, small molecule, liver-selective glucokinase (GK) activator-TTP399 as a potential diabetes treatment.

https://fdaheadlines.com/vtv-therapeutics-inc-nasdaqvtvt-announces-the-publication-of-detailed-data-showcasing-the-discovery-and-development-of-ttp399-and-the-results-of-phase-2-agata-study/